These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cyclooxygenase 2 promoter-based replication-selective adenoviral vector for hypopharyngeal cancer.
    Author: Nakagawa T, Tanaka H, Shirakawa T, Gotoh A, Hayashi Y, Hamada K, Tsukuda M, Nibu K.
    Journal: Arch Otolaryngol Head Neck Surg; 2009 Mar; 135(3):282-6. PubMed ID: 19289707.
    Abstract:
    OBJECTIVE: To explore the potential clinical application of the oncolytic activity of cyclooxygenase 2 (COX-2) promoter-based, conditional, replication-selective adenovirus vector for hypopharyngeal squamous cell carcinoma. DESIGN: In vivo study and retrospective study. SETTING: Kobe University Hospital, Kobe, Japan. SUBJECTS: Expression of COX-2 in hypopharyngeal cancers treated at Kobe University Hospital was immunohistochemically investigated. In addition, nude mice bearing human hypopharyngeal cancer cells (H891) were used to analyze oncolytic activity of a conditional replication-selective adenovirus vector in which the expression of E1a, required for viral replication, is controlled by the COX-2 promoter Ad-COX2-E1a. RESULTS: In vivo assays showed significant growth suppression in the murine hypopharyngeal model. Cyclooxygenase 2 expression was observed in 75.3% of hypopharyngeal cancers, especially in differentiated tumor cells (P = .001; r = 0.433). CONCLUSION: In this study, we demonstrated the potential of oncolytic therapy using the COX-2-promoter based, conditional, replication-selective adenovirus for COX-2-expressing hypopharyngeal squamous cell carcinomas.
    [Abstract] [Full Text] [Related] [New Search]